London, Ontario – TheNewswire - September 8, 2025 - Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced it will be participating in the upcoming H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025.

Jonathan Rigby, Sernova’s President and CEO, will provide a company overview in a virtual presentation and will be participating in virtual one-on-one investor meetings. Please contact your representative at H.C. Wainwright to schedule a meeting with the management team during the conference.

ABOUT SERNOVA BIOTHERAPEUTICS

Sernova Biotherapeutics is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem-cell derived islet-like clusters in collaboration with Evotec to create bio-hybrid organs to treat T1D. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on T1D and thyroid disorders.

FOR FURTHER INFORMATION, PLEASE CONTACT:

David Burke VP, Investor Relations (917) 751-5713

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Website: https://sernova.com/ 

The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release.